Education
About Us
Working with TipRanks
Follow Us
Tissue Repair Ltd (AU:TRP)
ASX:TRP
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$10.88M
Enterprise Value-AU$1.43M
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration & High Gross MarginsSustained revenue acceleration alongside very high gross margins suggests emerging product or program traction and unit economics that can scale. Over 2-6 months this supports durable commercial optionality and reduces the scale of future funding needed if growth persists.
Zero Debt Balance SheetA debt-free balance sheet materially lowers financial distress risk through clinical development. This structural strength preserves optionality for equity, partnership, or milestone financing and reduces near-term liquidity pressure compared with leveraged peers.
Proprietary Platform & Focused Clinical PipelineOwning a proprietary tissue-repair platform and a focused clinical program creates a durable competitive advantage: potential multiple assets, licensing or partnership opportunities, and clearer clinical development pathways that support long-term value creation.
Bears Say
Persistent Negative Cash Flow & Rising Cash BurnConsistent negative operating and free cash flow with worsening FCF indicates structural cash burn. Over the medium term this raises the likelihood of dilutive financing or needed partnerships, constraining execution pacing and negotiating leverage for clinical advancement.
Deep Ongoing Losses & Negative MarginsExtremely negative margins reflect a business still in heavy investment mode where losses far exceed revenue. This limits self-funding capacity, stresses return metrics, and prolongs dependence on external capital until material clinical or commercial inflection points occur.
Declining Equity And Elevated Funding/dilution RiskMaterial erosion of shareholder equity over several years signals cumulative losses and a shrinking capital buffer. This structural deterioration increases the probability and potential severity of future dilutive raises, which can impair long-term shareholder value.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.17 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$10.88M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Feb 19, 2026 which is in 2 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Aug 29, 2025. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$8.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-26.53%
Trailing 12-Months
Asset Growth
-24.84%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―